NERM
BIIB icon

New England Research & Management’s Biogen BIIB Stock Holding History

New England Research & Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,375
Closed -$368K – 138
2020
Q2 		$368K Buy
+1,375
New +$413K 0.26% 111
2020
Q1 		– Sell
-1,150
Closed -$341K – 139
2019
Q4 		$341K Buy
+1,150
New +$319K 0.23% 122
2015
Q4 		– Sell
-900
Closed -$263K – 166
2015
Q3 		$263K Buy
900
+200
+29% +$66K 0.25% 131
2015
Q2 		$283K Buy
+700
New +$281K 0.23% 138

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

New England Research & Management's BIIB Position: Q3 2020 in Review

New England Research & Management sold out of Biogen (BIIB) in Q3 2020, closing a stake of 1,375 shares — an estimated $368K sold.

New England Research & Management first reported a position in BIIB in Q2 2015 and held it in 4 quarters. The position peaked at $368K in Q2 2020. 1,051 funds tracked by Wall St. Rank hold BIIB as of Q3 2020.

  • New England Research & Management reported no remaining Biogen position as of Q3 2020 after selling out during the quarter.
  • New England Research & Management sold 1,375 Biogen shares in Q3 2020, an estimated $368K.
  • New England Research & Management first reported a position in Biogen in Q2 2015 and held it in 4 quarters.
  • New England Research & Management's Biogen position peaked at $368K in Q2 2020.
  • 1,051 funds tracked by Wall St. Rank held Biogen as of Q3 2020.

Based on New England Research & Management's 13F filing for Q3 2020, filed 8 Oct 2020.